News - Lucentis, Avastin

Filter

Current filters:

LucentisAvastin

Popular Filters

Avastin could save the USA $29 billion if used instead of Lucentis

Avastin could save the USA $29 billion if used instead of Lucentis

04-06-2014

Using Avastin (bevacizumab) from Swiss drug major Roche instead of Lucentis (ranibizumab) from fellow…

AvastinBevacizumabFinancialLucentisNovartisOphthalmicsPharmaceuticalRocheUSA

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

BIA warns that UK government pricing proposals would damage UK biotech

20-08-2013

The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…

AvastinBayerEuropeEyleaFinancialLucentisPharmaceuticalPoliticsPricingRegeneronRoche

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe

28-11-2012

Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report

24-07-2012

After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

New study fuels already heated debate - Avastin vs Lucentis

19-06-2012

At the center of the debate of how to potentially save the health care system millions of dollars are…

AvastinLucentisNovartisOphthalmicsPricingResearchRoche

Second trial finds Avastin and Lucentis similar for wet-AMD

08-05-2012

One-year results from the UK.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN)…

AvastinLucentisNovartisOphthalmicsPharmaceuticalPricingResearchRoche

US retinal therapeutics market buoyant, says F&S

07-05-2012

Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering…

AvastinGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRoche

Avastin and Lucentis equivalent in treating age-related macular degeneration

02-05-2012

At two years, the cancer drug Avastin (bevacizumab) and the ophthalmic agent Lucentis (ranibizumab injection),…

AvastinLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Novartis posts sharp drop in 1st-qtr profit; challenges UK off-label Avastin use

24-04-2012

Swiss drug major Novartis (NOVN: VX) has reported a sharp fall in first-quarter 2012 profits, due in…

AvastinEuropeFinancialGenericsLegalLucentisNovartisOphthalmicsPharmaceutical

Back to top